{"doi":"10.1002/nep3.8","title":"Join us on an amazing journey towards next‐generation treatments for CNS disorders: Launch of <i>Neuroprotection</i>, a new high‐quality journal in translational neuroscience","abstract":"Translational medicine in neurodegenerative and neurovascular diseases is approaching a breakthrough point. Recent years have led to dramatic progress in both experimental and clinical research. Based on a much better and continuously increasing understanding of disease mechanisms, progression and pathophysiology, new therapies with an improved translational potential to protect tissue either against acute or chronic degeneration and even approaches potentially capable of repairing damaged brain tissue are emerging. Importantly, the field has learned from previous translational setbacks as the internal and external validity of experimental studies are continuously improving. This is paralleled by an increase in the number of clinical trials aimed at establishing new therapeutic approaches. For instance, neuroprotection is currently seeing a renaissance in the areas of stroke and traumatic brain injury research and treatment. The translational failure of early neuroprotective paradigms for stroke which rely on systemic administration of neuroprotectants during acute and subacute stages has been reported and analyzed in detail. Whereas previous preclinical research and the translation of results obtained therein into clinical treatments were often impaired by shortcomings in experimental design, research quality in the field has improved substantially and methodological rigor applied today is outstanding across many fields.1 Moreover, the era of recanalization therapies now offers the possibility to apply neuroprotective treatments locally, when and where they are needed.2 Moreover, the application strategies for neuroprotectants have been greatly refined. Indeed, contemporary approaches do not focus primarily on permanent neuroprotection trying to rescue larger parts of infarcted brain tissue by targeting single pathomechanisms. Instead, they use elaborate approaches to protect the penumbra in order to gain time for recanalization, to prevent reperfusion injury, or to target different brain resident cells in their respective protective time windows.3 Many of these approaches are safe to be applied in a prehospital setting, opening new ways for more targeted and effective ‘2nd generation’ neuroprotective treatment paradigms. Moreover, these new paradigms are developed to be fully compatible with established treatment procedures including recanalization approaches.4 Similar progress is reported in other fields. For example, a recent double-blind and randomized phase II clinical trial in multiple sclerosis (MS) revealed preliminary evidence for a modest yet clinically meaningful therapeutic effect of mesenchymal stem cell (MSC) transplantation.5 MSCs can exert therapeutic effects via the secretion of numerous growth factors and have strong immunomodulatory abilities, making them an ideal resource for central nervous system regenerative medicine and beyond. Indeed, MSC transplantation was accompanied by a marked reduction of cerebrospinal fluid levels of neurofilament L, indicating neuronal loss, and CXCL-13, a potent B-cell chemoattractant and biomarker for active lesions in MS. Recent studies have evaluated the therapeutic potential of rasagiline, a monoamine oxidase B inhibitor, regarding its neuroprotective potential in Parkinson's disease (PD) and in amylotrophic lateral sclerosis (ALS). In PD, rasagiline was used as an add-on to the standard levodopa treatment in a Japanese cohort enrolled into a randomized, double-blind, placebo-controlled, Phase II/III clinical trial. Rasagiline reduced OFF-time and improved symptoms in ON-time as measured by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale scores.6 A subsequent trial investigating the impact of rasagiline in ALS did not indicate overall efficacy but post-hoc analyses suggested that rasagiline may provide benefits in some ALS patient subgroups.7 To further highlight recent advancements in understanding mechanistic insight, where we once thought monoami","journal":"Neuroprotection/Neuroprotection (Chichester, England. Print)","year":2022,"id":304210,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9494,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":416236,"name":"Piotr Walczak","orcid":"0000-0002-3733-3322","position":1,"is_corresponding":false},{"id":65664,"name":"Heleen M.M. van Beusekom","orcid":"0000-0002-2930-1152","position":2,"is_corresponding":false},{"id":997015,"name":"Ana I. Casas","orcid":"0000-0002-0935-074X","position":3,"is_corresponding":false},{"id":482996,"name":"Andrew N. Clarkson","orcid":"0000-0003-3804-3834","position":4,"is_corresponding":false},{"id":997016,"name":"Tracy D. Farr","orcid":"0000-0002-6781-5226","position":5,"is_corresponding":false},{"id":997017,"name":"Jukka Jolkkonen","orcid":"0000-0002-9858-0204","position":6,"is_corresponding":false},{"id":566037,"name":"Yajie Liang","orcid":"0000-0002-4798-4882","position":7,"is_corresponding":false},{"id":997018,"name":"Michel Modo","orcid":"0000-0003-4436-735X","position":8,"is_corresponding":false},{"id":997019,"name":"Paulo Henrique Rosado-de-Castro","orcid":"0000-0003-0091-9714","position":9,"is_corresponding":false},{"id":997020,"name":"Karsten Ruscher","orcid":"0000-0001-7211-2499","position":10,"is_corresponding":false},{"id":428230,"name":"Yan‐Jiang Wang","orcid":"0000-0002-6227-6112","position":11,"is_corresponding":false},{"id":997021,"name":"Haitao Wu","orcid":"0000-0001-8437-3194","position":12,"is_corresponding":false},{"id":867720,"name":"Marietta Zille","orcid":"0000-0002-0609-8956","position":13,"is_corresponding":false},{"id":576947,"name":"Shen Li","orcid":"0000-0003-2947-3787","position":14,"is_corresponding":false},{"id":851068,"name":"Johannes Boltze","orcid":"0000-0003-3956-4164","position":15,"is_corresponding":false},{"id":320471,"name":"Xunming Ji","orcid":"0000-0003-0293-2744","position":0,"is_corresponding":true}],"reference_count":13,"raw_metadata":null,"created_at":"2026-07-19T00:32:32.651796Z","pmid":"37701815","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}